Daily Ards Research Analysis
Analyzed 12 papers and selected 3 impactful papers.
Summary
Analyzed 12 papers and selected 3 impactful articles.
Selected Articles
1. A brain-lung circuit drives LPS-induced lung injury via sympathetic neutrophil axis.
Using an intraperitoneal LPS model, the authors show that systemic inflammation robustly activates PVN CRH neurons and that subdiaphragmatic vagotomy abolishes this neural response. These data implicate a brain–lung circuit operating through a sympathetic–neutrophil axis in driving inflammatory lung injury.
Impact: This study identifies a central neuroimmune driver of sepsis-related lung injury, linking hypothalamic stress circuitry to peripheral neutrophil-mediated inflammation.
Clinical Implications: Findings support evaluating neuromodulatory strategies (e.g., vagal/sympathetic modulation or stress-axis targeting) as adjuncts in sepsis-associated ARDS.
Key Findings
- Systemic LPS strongly activates CRH neurons in the hypothalamic PVN.
- Bilateral subdiaphragmatic vagotomy abolishes the CRH neuronal activation induced by systemic inflammation.
- A brain–lung circuit via a sympathetic–neutrophil axis is implicated in driving LPS-induced lung injury.
Methodological Strengths
- Causal probe using bilateral subdiaphragmatic vagotomy to test necessity of vagal signaling.
- Physiologically relevant systemic LPS model of sepsis-related lung injury with neural activity mapping.
Limitations
- Preclinical animal model without human validation.
- Specific downstream nodes linking PVN activity to neutrophil responses require further delineation.
Future Directions: Map the full sympathetic–immune circuitry, test neuromodulatory interventions, and validate biomarkers and mechanisms in human sepsis/ARDS cohorts.
Acute respiratory distress syndrome (ARDS) is a fatal complication of sepsis. However, the neural mechanisms underlying the exacerbation of pulmonary inflammation during systemic infection remain largely undefined. We employed an intraperitoneal lipopolysaccharide (LPS)-induced systemic inflammatory lung injury model and found that systemic inflammation strongly activates corticotropin-releasing hormone (CRH) neurons in the paraventricular nucleus (PVN), whereas bilateral subdiaphragmatic vagotomy abolished this response. Chemogenetic inhibition of CRH
2. Sympathetic signaling activation alleviated acute respiratory distress syndrome via the HDC/SLC7A11 axis in lipopolysaccharide-induced macrophages.
Norepinephrine limited lipid peroxidation, preserved mitochondrial integrity, and upregulated SLC7A11/GPX4 in LPS-treated alveolar macrophages, effects blunted by β2-AR blockade or HDC knockdown. In septic mice, salbutamol increased SLC7A11/GPX4 and HDC in alveolar macrophages, reduced lipid peroxidation, and mitigated macrophage and lung injury, highlighting an HDC/SLC7A11 axis.
Impact: This work uncovers a neuroimmune ferroptosis-regulatory axis in alveolar macrophages and suggests β2-adrenergic agonists as potential adjunctive therapies for ARDS.
Clinical Implications: Findings support mechanistic rationale to evaluate β2-agonists (e.g., salbutamol) as adjuncts to limit macrophage ferroptosis in sepsis-associated lung injury, while carefully assessing systemic effects.
Key Findings
- Norepinephrine protected LPS-treated alveolar macrophages by limiting lipid peroxidation, preserving mitochondrial integrity, and upregulating SLC7A11 and GPX4.
- β2-adrenergic receptor blockade or HDC knockdown attenuated the anti-ferroptotic effects of norepinephrine.
- In vivo, salbutamol increased SLC7A11/GPX4 and HDC expression in septic mice and reduced lipid peroxidation and lung injury.
- Identifies HDC/SLC7A11 as a neuroimmune axis regulating ferroptosis in alveolar macrophages.
Methodological Strengths
- Convergent in vitro and in vivo validation of mechanism.
- Mechanistic perturbations using β2-AR pharmacology and HDC knockdown to test causality.
Limitations
- Preclinical models; no human clinical outcome data.
- Heterogeneity of ARDS etiologies may limit generalizability of a single neuroimmune axis.
Future Directions: Validate the HDC/SLC7A11 pathway in human alveolar macrophages, define optimal β2-agonist dosing/timing, and assess safety/efficacy in early-phase clinical trials.
Acute respiratory distress syndrome (ARDS) represents a severe pulmonary condition characterized by excessive inflammation, wherein alveolar macrophages (AMs), pivotal components of the innate immune system, play a critical role in the pathogenesis of the disease. Despite its high morbidity and mortality, effective targeted therapies for ARDS remain unavailable. Norepinephrine (NE) is an endogenous neurotransmitter with immunomodulatory and anti-inflammatory properties, and has been reported to mitigate ARDS symptoms in sepsis models. While sympathetic signaling exerts protective effects, the underlying immunomodulatory mechanisms-especially those involving macrophages-remain poorly defined. Our in vitro experiments demonstrated that NE confers protection against LPS-induced injury in AMs by limiting lipid peroxidation, sustaining mitochondrial integrity, and upregulating antioxidant regulators SLC7A11 and GPX4, leading to improved cell viability. Mechanistically, the anti-ferroptotic effect of NE on LPS-treated AMs was significantly impaired by β2-adrenergic receptor (β2-AR) blockade or knockdown of histidine decarboxylase (HDC). Our in vivo experiments further demonstrated that salbutamol, a selective β2-AR agonist, upregulated SLC7A11 and GPX4 expression in septic mice and concurrently increased HDC expression in AMs. Furthermore, salbutamol alleviated lipid peroxidation, mitigated macrophage and lung tissue injury. These findings identify HDC/SLC7A11 as a potential axis involved in the neuroimmune regulation of ferroptosis in AMs, offering a potential therapeutic target for ARDS.
3. MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD.
This review situates DAD as the shared pathological substrate across ARDS, severe COVID-19, and RP-ILD, and aligns MSC/EV immunomodulatory, anti-apoptotic, reparative, and anti-fibrotic mechanisms with DAD stages. It proposes a mechanism-driven paradigm to guide clinical translation of MSC/EV therapies.
Impact: By integrating DAD pathophysiology with MSC/EV mechanisms across diseases, the review offers a scaffold for rational trial design and biomarker development.
Clinical Implications: Supports mechanism-based selection of MSC/EV products, dosing, and endpoints targeting DAD hallmarks to improve translational success.
Key Findings
- DAD underlies acute lung injury across ARDS, severe COVID-19, and RP-ILD, featuring epithelial/endothelial injury, inflammatory storm, and fibrotic remodeling.
- MSCs and EVs exhibit immunomodulatory, anti-apoptotic, tissue-repair, and anti-fibrotic properties relevant to DAD.
- The review correlates DAD stages with MSC/EV mechanisms and advocates a mechanism-driven therapeutic paradigm to guide clinical translation.
Methodological Strengths
- Mechanism-focused synthesis linking pathology stages to therapeutic mechanisms across multiple diseases.
- Cross-disciplinary integration that informs translational trial design.
Limitations
- Narrative synthesis; potential publication and selection biases cannot be excluded.
- Heterogeneity in MSC/EV sources, dosing, and delivery complicates direct comparison.
Future Directions: Standardize MSC/EV manufacturing and dosing, develop DAD-aligned biomarkers, and conduct mechanism-anchored randomized trials.
Diffuse alveolar damage (DAD) is the core pathological process of acute lung injury, characterized by dual injury to alveolar epithelial and capillary endothelial cells, initiation of an inflammatory storm, and subsequent fibrotic remodeling, with persistently high clinical mortality. This pathological change is not restricted to a single disease but widely exists in critical pulmonary disorders such as acute respiratory distress syndrome (ARDS), severe COVID-19, and rapidly progressive interstitial lung disease (RP-ILD), acting as a key driver of disease progression. In recent years, mesenchymal stromal cells (MSCs) and their derived extracellular vesicles (EVs) have become research hotspots for their superior immunomodulatory, anti-apoptotic, tissue-repair, and anti-fibrotic properties. Based on the DAD pathological framework, this article systematically correlates epithelial barrier injury, inflammatory cascade amplification and pulmonary fibrotic remodeling with the therapeutic mechanisms of MSCs and their derived EVs in ARDS, COVID-19 and RP-ILD. It aims to provide a solid basis for the clinical translation of MSCs- and EVs-based therapies and promote their development into a mechanism-driven therapeutic paradigm targeting DAD, with great clinical value and academic innovation.